Aravax appoints Financial Executive Thomas Ulmer to Board of Directors


01 November, 2020, Melbourne, Victoria - Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, announced today the appointment of Thomas Ulmer to the Board of Directors. Mr. Ulmer was previously the Chief Financial Officer of Immatics N.V., a NASDAQ-listed biopharmaceutical company and brings nearly two decades of experience serving in financial leadership positions across small, medium and large size healthcare companies.


“With extensive global experience in our industry working with private and listed companies and diverse shareholder structures, Mr Ulmer will be a significant asset to the Aravax Board of Directors.” Aravax CEO Dr Pascal Hickey said. “We are delighted to have Mr Ulmer on the board to advise on the direction of all financial matters and work with the team to develop Aravax’s corporate strategy.


Read More






Aravax Thomas Ulmer Board Appointment 1N
.
• 98KB

Archive